Previous studies have demonstrated that the onset of AKR leukemia could be dramatically delayed and the overall incidence significantly reduced following treatment with high-titered heterologous antibodies directed against the gp7l major glycoprotein of the virus. However, to be maximally successful, the treatment had to be initiated during the postnatal period of the AKR mouse, encompassing a narrow window representing approximately the first 3 days of life. In the present study we sought to extend this barrier by including antibodies directed against a second envelope component of the virion, the transmembrane protein, pl5E. We demonstrate that although neither antibodies to gp7l nor antibodies to pl5E could influence the course of leukemia development when applied individually later in life, a combination of the two antibodies was effective even if given as late as 5 months after birth. The significance of these studies is discussed in relation to human retrovirus-associated diseases.
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The processes by which antibodies to the viral gp7l glycoprotein can interrupt the events leading to development of spontaneous leukemia in the AKR mouse have been partially studied (1) (2) (3) (4) (5) . Examination of the natural history of the AKR retrovirus during the early stages of life has provided evidence that virus produced in the bone marrow and spleen migrates to the thymus and establishes a productive infection during the first week after birth. If anti-gp7l antibody of sufficient potency is applied during this period, no infectious cell centers are established in thymus (6, 7) . Subsequently, the mouse acquires immunocompetence and develops its own immune response against the virus manifested by both binding and neutralizing antibodies (2) (3) (4) . The inability to establish an infection in the thymus would tend to reduce the possibility of recombinational events between the ecotropic and xenotropic AKR viruses that are thought to be critical for eventual leukemia develolpment (8) .
From another perspective, our failure to alter these events when large amounts of antibody to gp7l were applied beyond the first week of life is puzzling since the level of viremia through 3 months of age remains quite low (9) . It is thus difficult to explain why a high-titered antibody to gp7l would not be able to suppress the virus to the point that the mouse could develop its own immunity. We thus considered the relevance of the observation that natural antibodies to endogenous viruses in low leukemic mouse strains typically possess reactivities not only to gp7l but also to the transmembrane piSE component (10) (11) (12) . These antibodies are quite unique in that those reacting with gp7l are type specific, whereas antibodies directed at pl5E recognize the analogous component of retroviruses from widely different species (unpublished observation). A singular property of pi5E is its ability to suppress a broad range of humoral and cellular immune functions in the mouse (13) and cat (14) as well as in man (15) . This might endow the virus with one avenue of escape from immune surveillance, thereby enhancing its leukemogenic potential. Indeed, a number of immune abnormalities have been noted in AKR mice that are most pronounced during the leukemic phase but are also detectable well before the onset of disease (16) . Thus, we reasoned that the presence of functional anti-pl5E antibodies may play a role in preventing the immunosuppressive effects of the pi5E peptide.
The studies described in this report were aimed toward determining the role of anti-pl5E antibodies in leukemia development in the AKR mouse. We have compared autogenous antibodies administered through foster nursing or by direct inoculation with high-titered heterologous antibodies against gp7l and plSE given alone or in combination. Our results demonstrate that antibodies directed against the transmembrane component can markedly extend the previously described therapeutic window early in life such that one can intervene with the course of leukemia development as late as 5 months of age or just prior to the onset of disease progression. These findings may be relevant to the problems associated with human retroviruses, particularly in acquired immunodeficiency syndrome (AIDS), where the immunosuppressive aspects of virus infection are paramount (17) .
MATERIALS AND METHODS
Mice. (i) AKRFRED mice: High leukemic (>90%) AKR mice were obtained from the breeding facility of the Frederick Cancer Research Center (Frederick, MD). They were maintained as inbred mice at the Max-Planck Institut in Tubingen (F.R.G.) (4) .
(ii) AKRDAN mice: High leukemic (>90%o) AKR mice were obtained from Gl. Bomholtgard Ltd. (Ry, Denmark) (2) .
(iii) AKRFRED-imm. mice (where subscript imm. indicates immunized): These animals represent AKRFRED mice that were protected against leukemia development after treatment as newborns with anti-FLV-gp7l antibody (FLV, Friend leukemia virus) (4) . They all possessed high antibody titers to the virus in radioimmunoprecipitation (RIP) (-1350 ited a very low incidence of leukemia (=z5%) and possessed autogenous RIP antibody titering between 150 and .1350 (3) .
(v) STU mice: This highly inbred low leukemic (=4%) mouse strain was developed in the Max-Planck Institut in Tubingen (12, 18) . All mice are RIP positive with titers ranging from 150 to -1350.
Antibodies. The antibodies used and their properties are illustrated in Table 1 and additional information is given in Fig. 1 . Antibodies (and the respective IgG fractions) against FLV-gp7l were produced in a goat and those against FLVpi5E were produced in a rabbit according to procedures described earlier (19, 20) .
For preparation of IgG from the mouse sera, these were first diluted with an equal volume of 0. (22) , analyzed on slab gels (23) , and processed for fluorography according to a published procedure (24) .
RESULTS

Transmission of Protection by Female
Mice Possessing Antiviral Antibodies. In earlier studies, we reported that a significant proportion of AKR mice treated with heterologous anti-gp7l antibodies at birth could escape leukemia development during their normal life span (1) (2) (3) (4) . Curiously, the consequences of such treatment were distinguishable in two separate AKR strains: one obtained from Denmark (3), the other from the Frederick Cancer Center (4). Danish AKR mice (AKRDAN) that were protected by anti-gp7l antibodies (AKRDAN-imm.) could be inbred to yield offspring that were virtually free of leukemia. Characteristically these mice exhibited high titers of antibodies to gp7l and pi5E ( Fig. 1 ; Table 2 ). A similar spectrum of reactivity is commonly found in low leukemic strains, an example of which are STU mice, a highly inbred strain derived in one of our laboratories (12, 18) ( Fig. 1 ; Table 2 ). On the other hand, Frederick AKR mice (AKRFRED), though also capable of being protected by anti-gp7l antibodies (AKRFRED-imm.), were unable to transmit this feature to their offspring (4). Of interest is that the antibody spectrum of AKRFRED-imm. is qualitatively different from that observed in AKRDAN imm. mice. As seen in Fig. 1 , AKRFRED-imm. mice display a much weaker anti-pi5E reactivity when compared to that in serum of the low leukemic AKRDAN-imm. and STU strains, where the anti-plSE reactivity actually dominates that seen with anti-gp7l. Finally, untreated AKRFRED mice do not exhibit any antiviral antibodies in the serum (Fig. 1 ) and are associated with a high incidence of leukemia.
Given these observations, it was of interest to determine whether foster nursing of high leukemic weanling AKRFRED mice onto female mice of the low leukemic STU as well as the AKRDAN-imm. and AKRFRED-imm. strains might reveal whether or not the respective antibody spectrum was of biological significance. The effect of these manipulations on the incidence of leukemia is demonstrated (Fig. 2) tPooled sera from 10-20 mice (taken soon before giving birth or use as a nurse) were allowed to react with radioactive MCF virus and the precipitate was analyzed by NaDodSO4/PAGE. The respective bands were cut from the gel and the radioactivity was determined (see Fig. 1 ). §Measured at 4-5 months of age.
91Determined from Fig. 2 . Also shown in Fig. 2 (Fig. 1) , it is possible to establish the respective ratios (gp71:pl5E/pl2E) shown in Table 2 also Table 4 ). v, Anti-plSE-treated mice; c, anti-gp7l-treated mice; a, anti-plSE-plus anti-gp7l-treated mice; *, AKRFRED control mice.
beyond the therapeutic window established with anti-gp7l antibodies alone. The results of these studies are shown in Fig. 3 and summarized in Table 4 , with the characteristics of the respective sera given in Table 1 and Fig. 1 .
The outcome demonstrates that virtually no effects are noted with either antibody alone when applied at 2V2 and 5 months of age as in the case of anti-pl5E or at 5 months with anti-gp7l (Table 4 ; Fig. 3 ). In earlier studies no effect was seen when treatment with anti-gp71 was initiated at 39 days (5). On the other hand, a combination of the two antibodies resulted in a clear suppression of leukemia when given at 5 months of age (Fig. 3) . Similar results were achieved when an analogous long-term treatment was initiated at 2V2 months (5) . The magnitude of this effect is comparable to that seen when AKR mice are treated immediately after birth with anti-gp7l antibodies alone. Not shown in this regard are results indicating that anti-plSE alone had no effect when given immediately after birth (5) . Likewise, if treatment with anti-gp7l and -pl5E IgG was limited to 10-12 days instead of 42 days, no beneficial effects were observed using comparable amounts of IgG (not shown). Thus, a more prolonged treatment might be of further benefit. On the other hand, administration of both antibodies after onset of leukemia had no effect on the outcome of disease regardless of the length of treatment.
As noted in previous reports (1) (2) (3) (4) , the development of anti-AKR virus antibody correlated with protection against disease. However, in this study we observed the appearance of low but measurable RIP titers in mice treated with tSee footnote t in Table 3. tNot determined; died soon after termination of IgG treatment (see Fig. 3 ).
anti-gp7l antibodies at 5 months of age as well as with anti-pl5E antibodies at 2V months of age ( The fact that neither anti-gp7l nor anti-pl5E alone is therapeutic either in autologous or heterologous form but that both are required simultaneously to suppress leukemia deserves further consideration. We would interpret this result to mean that after AKR viremia becomes established, antigp7l antibodies, though able to reduce the virus load during treatment, are unable to cope with the negative effects of pi5E, which would tend to promote leukemia development. Similarly, though anti-p15E might be capable of blocking some of these effects, viremia itself and thus continuous pi5E production would not be affected. When the antibodies are present together, both the virus and its harmful gene products would be suppressed.
These observations may be directly relevant to the situation in the retrovirus-mediated events that lead to the development of AIDS. In general, these and other studies (35) provide a rationale for use of virus envelope components as targets for immunological prevention and intervention in retrovirus-associated diseases. In particular, the present study highlights the importance of antibodies directed against the transmembrane element of the virus (25) . This component of retroviruses is highly conserved (28, 36) , and homologous segments of certain animal retrovirus transmembrane proteins are found even in human retroviruses (28) . Though it remains to be determined whether or not the gp4l transmembrane protein of human T-lymphotrophic virus, type III/lymphoadenopathy-associated virus (now designated human immunodeficiency virus) (37), possesses immunosuppressive properties, this is a likely possibility. Furthermore, the recent demonstration that portions of gp4l may determine the pathogenicity of the virus (38) further highlights the significance of this molecule. Thus, antibodies against the outer envelope and the transmembrane component of the virus might be an effective regimen to adopt for intervention during the early stages of exposure to human retroviruses associated with AIDS as well as other diseases.
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